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Abstract 
Background 
BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the Fanconi Anaemia Complementation 
(FANC) group family of DNA repair proteins. Biallelic mutations in BRIP1 are responsible for FANC group J, 
and previous studies have also suggested that rare protein truncating variants in BRIP1 are associated with an 
increased risk of breast cancer. These studies have led to inclusion of BRIP1 on targeted sequencing panels for 
breast cancer risk prediction.  
Methods 
We evaluated a truncating variant, p.Arg798Ter (rs137852986), and 10 missense variants of BRIP1, in 48,144 
cases and 43,607 controls of European origin, drawn from 41 studies participating in the Breast Cancer 
Association Consortium. Additionally, we sequenced the coding regions of BRIP1 in 13,213 cases and 5,242 
controls from the UK, 1,313 cases and 1,123 controls from three population-based studies as part of the Breast 
Cancer Family Registry, and 1,853 familial cases and 2,001 controls from Australia. 
Results 
The rare truncating allele of rs137852986 was observed in 23 cases and 18 controls in Europeans in BCAC (OR 
1.09, 95% CI 0.58-2.03, P = 0.79). Truncating variants were found in the sequencing studies in 34 cases 
(0.21%) and 19 controls (0.23%) (combined OR 0.90, 95% CI 0.48-1.70, P=0.75). 
Conclusions 
These results suggest that truncating variants in BRIP1, and in particular p.Arg798Ter, are not associated with a 
substantial increase in breast cancer risk. Such observations have important implications for the reporting of 
results from breast cancer screening panels. 
Keywords 
BRIP1 gene, mutation, breast cancer 
 
Introduction 
Susceptibility to breast cancer is known to be mediated through a very large number of genetic variants 
conferring a wide range of disease risks relative to population incidence rates
1
. These variants include rare 
mutations in high-penetrance genes (4-fold or higher risk), notably BRCA1 and BRCA2, mutations in genes 
conferring more moderate risks of breast cancer (2- to 4-fold higher risks), and approximately 100 common 
susceptibility variants (SNPs) conferring modest risks of the disease (typically 1.1-1.2 fold). Clinical genetic 
testing for breast cancer has largely focussed on the high-risk genes. However, with the increasing use of high-
throughput sequencing, genetic testing is being extended to larger panels of genes, including those in the 
“moderate risk” category2.  
The known genes in the moderate risk category encode proteins involved in DNA repair. One of the genes 
involved in DNA repair that has been proposed as a breast cancer susceptibility gene is BRIP1. BRIP1 
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(BRCA1-interacting protein 1, also known as BACH1) encodes a helicase-like protein that was identified via its 
direct binding to the BRCA1 BRCT domains, and is known to contribute to DNA repair via homologous 
recombination
3 4
. BRIP1 was shown to be the likely causative gene for Fanconi Anaemia complementation 
group J through positional cloning and the identification of germline mutations in nine families from two 
studies
4 5
. The most common truncating mutation identified was c.2392C>T (p.Arg798Ter) in exon 17. Analysis 
of a cell line from a patient homozygous for this mutation showed complete absence of the full length BRIP1 
protein
4
. p.Arg798Ter has been found in patients from diverse populations, suggesting that it is either a 
relatively ancient founder mutation or is recurrent.  
Given the role of BRCA1 and other genes involved in DNA repair in susceptibility to breast and other cancers, it 
seems reasonable to speculate that germline mutations of BRIP1 might also predispose to breast cancer. Seal et 
al
6
 screened the coding sequence of 1,212 women with breast cancer having a family history of disease and 
2,012 controls. They identified mutations predicted to lead to a truncated protein in nine cases versus two in 
controls: an estimated relative risk of breast cancer, after adjustment for oversampling of cases with a family 
history, of 2.0 (95%CI 1.2-3.2, P=0.012). The most common mutation was p.Arg798Ter, accounting for five of 
the mutations in cases and one in controls. 
Since the Seal et al
6
 paper, several other studies have identified BRIP1 variants through screening of breast 
cancer cases for specific mutations
7-12
, but no large-scale case-control mutation screening studies have been 
reported. To evaluate more definitively the evidence that BRIP1 is a breast cancer susceptibility gene, we 
genotyped the p.Arg798Ter variant and 10 missense variants, in more than 48,000 cases and 43,000 controls in 
studies participating in the Breast Cancer Association Consortium (BCAC). Additionally, we screened the 
entire coding sequence of BRIP1 in three large case-control studies comprising more than 16,000 cases and 
8,000 controls.   
 
Methods 
Breast Cancer Association Consortium 
Breast cancer cases and controls were drawn from 52 studies participating in the Breast Cancer Association 
Consortium (BCAC). The analysis was restricted to 48,143 cases and 43,608 controls from 41 studies in 
populations of European origin (comprising ~87% of the dataset) since the sample sizes for Asian and African-
American women were too small for separate analysis. The truncating variant p.Arg798Ter and ten missense 
variants in BRIP1 (Table 1) were genotyped using iCOGS, a custom array of ~200,000 variants
13
. Genotypes 
were subject to standard quality control procedures as described previously
13
.  
For the purpose of this analysis we manually recalled the genotypes for BRIP1 p.Arg798Ter using the cluster 
plot of normalised intensities (Figure 1). The experiment included a positive control previously identified as a 
carrier of the mutant allele through sequencing of a series of prostate cancer cases. This individual was 
genotyped correctly as a variant carrier. We further confirmed the genotypes through comparison with data 
from two re-sequencing experiments conducted in SEARCH and the Breast Cancer Family Registry (BCFR), 
for which individuals were also genotyped using iCOGS (see below). Thirteen individuals in the former study 
and two in the latter study were identified as carrying the variant allele at p.Arg798Ter; genotypes determined 
by the two methods were 100% concordant.  
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SEARCH study 
Subjects: Cases were drawn from SEARCH, a population-based study of breast cancer in the region covered by 
the Eastern Cancer Registration and Information Centre (ECRIC), United Kingdom
14
. SEARCH recruited 
patients diagnosed with invasive breast cancer before the age of 55 years since 1991 and still alive at the start of 
the study in 1996 (prevalent cases; median age, 48 years), together with all those diagnosed before 70 years of 
age between 1996 and 2014. The study was approved by the Cambridgeshire Research Ethics Committee. The 
present analysis is based on data from 13,824 case participants. Controls were drawn from the EPIC-Norfolk 
study, a population-based cohort study of diet and health women attending GP practices, frequency matched to 
cases by age and geographic region (2003-present)
14
, and women attending breast screening as part of the 
National Health Service Breast Screening Program (NHSBSP) participating in the Sisters in Breast Screening 
(SIBS) study
15
. The final analyses were based on 13,213 cases and 5,242 controls that passed QC filters (see 
below). 
 
Mutation screening: Target enrichment was accomplished using the 48.48 Fluidigm Access Array system. This 
approach employed multiplexed microfluidic PCR reactions to first amplify targeted regions and then ligate one 
of 1,536 unique barcodes and sequencing adapters. To cover the 19 protein-coding exons and associated splice 
junctions of BRIP1, we designed 45 PCR amplicons that were 133-199 base-pairs (bp) in length, which together 
produced unique coverage of 3,750 bp, as part of a larger multiplex panel involving ~500 amplicons. The 
amplicon designs covered 100% of the targeted regions. Fourteen 1,536-sample sequencing libraries were 
produced according to the manufacturer’s protocol (Fluidigm, San Francisco, CA, US) and assayed with the 
KAPA library quantification kit with specific probes for the ends of the adapters (KapaBiosystems, Boston, 
MA, US). Libraries were sequenced in paired end mode on the Illumina HiSeq 2000 and CASAVA was used to 
construct demultiplexed sequence files, according to the manufacturers’ protocols (Illumina Inc., San Diego, 
CA, US). Cutadapt version 1.5 was used to remove primer sequences from both ends of each read, and 
untrimmed reads were discarded
16
. Reads were aligned to the hg19 human genome reference sequence using 
BWA-MEM version 0.7
17
, and GATK version 3.3-0-g37228af was used for base quality score recalibration and 
indel realignment, and for deriving quality and depth metrics 
18
. BRIP1 was segmented into intervals of 2-7 
exons, and the GATK UnifiedGenotyper was used to perform SNP and indel discovery and genotyping across 
all samples simultaneously, according to GATK Best Practices recommendations
19
. The samples had a median 
coverage of 446.4, and a median of 97.47% of the targeted region (coding exons within 6 bp of flanking 
sequence) covered in each sample. In initial filtering, variants with >20% missing data were removed, and 
samples with no genotype at >20% of remaining positions were also excluded. Genotypes with depth <20 or 
genotype quality <13 were re-coded as no genotype. GATK was used to recalculate variant-level metrics 
without these failed samples and low-confidence genotypes, and positions genotyped in >95% of samples and 
with quality by depth between 3.0 and 25.0 were retained for further analysis. The remaining variants were 
annotated with CADD version 1.2
20
, and 40 truncating and predicted damaging missense variants were selected 
for Sanger sequencing. Of these 39 (positive predictive value 97.5%) variants were successfully confirmed.  
iCOGS data were available for 13,133 individuals that were also sequenced. Six rare coding variants 
(MAF<1%) were polymorphic in the iCOGS data. Of the 357 rare allele carriers identified by iCOGS, the 
sequencing identified 355 (99.4%), although for two of the variants (p.Val193Ile and p.Arg173Ser), 13/111 and 
17/138 of individuals called heterozygotes by iCOGS genotyping were called rare allele homozygotes by 
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sequencing, reflecting bias in PCR amplification. One common coding polymorphism (rs4986764, 
p.Ser919Pro) was concordant in 99.9% of samples.  
BCFR study 
Subjects: Eligible participants included women ascertained by population-based sampling by the Australia, 
Northern California, and Ontario sites of the BCFR between 1995 and 2005
21
. For the present study, the 
selection criteria for cases (n = 1,313) were diagnosis of breast cancer at < 45 years of age and self-reported 
race/ethnicity, plus grandparents’ country of origin information consistent with Caucasian, East Asian, 
Hispanic/Latino, or African American racial/ethnic heritage. The controls (n = 1,123) were frequency-matched 
to the cases within each center by racial/ethnic group, with age at selection not more than 10 years older or 
younger than the age at diagnosis of the cases ascertained at the same center. The design of this study has been 
described in detail previously
22-27
. Recruitment and genetic studies were approved by the Ethics Committee of 
the International Agency for Research on Cancer (IARC; Lyon, France), the University of Utah IRB, and the 
local IRBs of the BCFR centers from which samples were received. Written informed consent was obtained 
from each participant. 
Mutation screening: Mutation screening was carried out using 30ng of whole-genome amplified (WGA) DNA 
and covered the 19 coding exons of BRIP1 (NM_032043.2). The laboratory process has been described in detail 
for our recent studies of ATM 
22
, CHEK2
23
, XRCC2
24
,RAD51
25
, RINT1 
26
 and MRN genes 
27
. The semi-
automated approach relies on mutation scanning by high-resolution melt curve (HRM) analysis followed by 
direct Sanger sequencing of the individual samples for which an aberrant melt curve profile is indicative of the 
presence of a sequence variant. In our previous work, we showed, by comparing the results with those obtained 
with Sanger sequencing
28
, that the HRM technique showed high sensitivity and specificity (1.0, and 0.8, 
respectively, for amplicons of <400 bp) for mutation screening. All rare exonic variants, plus intronic variants 
that fell within 20bp of a splice acceptor site or 8bp of a splice donor site were independently re-amplified from 
the two WGA reaction products to confirm the presence of the variant using direct Sanger sequencing. Primer 
and HRM probe sequences are available from the authors upon request. 
Peter MacCallum Cancer Centre study 
Subjects: The familial cohort included 1,853 index individuals with personal and family histories of breast 
cancer who were previously assessed at Familial Cancer Centres in Victoria and New South Wales.  A total of 
979 cases were obtained from the ‘Variants in Practice’ (ViP) study which recruited via the combined Familial 
Cancer Centers (FCCs) in  Melbourne, Australia
29
, and 874 through the Hunter Area Pathology Service, 
Newcastle, Australia. All index cases were previously screened through their clinical genetics services and 
found to be negative for mutations in BRCA1 and BRCA2. Large deletions and duplications in BRCA1 and 
BRCA2 were included in the mutational analysis as determined by multiplex ligation-dependent probe 
amplification (MLPA) analysis.  The 2,001 female controls were accessed through Lifepool (www.lifepool.org) 
which is a cohort of women attending population mammography screening program in Victoria, Australia. 
Controls were aged 40 years and above (mean age 64) and were cancer-free at time of blood collection. This 
study was approved by the Hunter New England Human Research Ethics Committee and the Peter MacCallum 
Cancer Centre Human Research Ethics Committee. 
Mutation screening: Cases and controls were screened for germline mutations in all 19 exons of BRIP1 on the 
HiSeq 2500 System (Illumina) using the Haloplex target enrichment system (Agilent) as described previously
30
. 
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Paired-end sequence reads were aligned to the human genome (hg19 assembly) using the BWA-MEM 
software
31
. Base quality score recalibration and indel realignment was performed using the GATK software. 
Single nucleotide variants (SNVs) and indels were identified using the GATK Unified Genotyper and Variant 
Quality Score Recalibration 
18 19
. Variants were annotated with information from Ensembl release 62. The 
average percentage of bases covered at a depth of ≥10x was 94.8% for cases and 96.1% for controls with all 
samples having at least 85% of bases sequenced at a depth of ≥10x. 
All truncating variants in BRIP1 were validated by Sanger sequencing, as were any missense SNPs with a 
CADD score over 10 that had not been previously reported in any databases.  Previously reported SNPs were 
only validated in selected cases if the variant calling was unclear (quality score <150 or not identified in 
bidirectional reads).  
Statistical Analysis 
Association between each of the variants in BRIP1 and breast cancer risk was assessed in BCAC using logistic 
regression, with adjustment for study and seven principal components for women of European ancestry derived 
from genotypes of SNPs on the iCOGS array, as previously described
13
. For the three targeted sequencing 
studies, we carried out burden analyses, which evaluated the risk associated with carrying any one of a set of 
likely deleterious variants, since the variants were too rare to be analysed individually, and this is directly 
relevant to the potential clinical application of the findings of this study. We considered two sets of variants: 
those predicted to result in a truncated protein product; and missense substitutions with a CADD score > 20. 
Odds ratios (OR) and 95%  confidence intervals (CI) were calculated for each of the three individual studies 
(SEARCH, BCFR and Peter MacCallum) and combined with those for BCAC/iCOGS using fixed effects meta-
analysis.   Heterogeneity in the odds ratio among studies was assessed using a standard heterogeneity chi-
squared test and I
2
 statistic. 
The BCAC dataset partially overlapped with SEARCH and two of the BCFR studies (ABCFS and OFBCR). 
Since p.Arg798Ter failed the minimum coverage threshold in SEARCH, for simplicity we excluded the 
p.Arg798Ter variant, and two other missense variants (rs4988345 and rs28997569) that were genotyped on the 
iCOGS from both the SEARCH and BCFR sequencing data (but retained them in the BCAC dataset) when 
combining the results across all datasets. This resulted in an overlap in the (non-carrier) datasets between the 
BCAC, and the SEARCH and BCFR sequencing datasets, but the resulting bias in the combined odds ratio 
would be negligible since the variants are all extremely rare. The most probable haplotypes for markers across 
the BRIP1 region were generated using SHAPEIT v2
32
. 
Nonsense-mediated mRNA decay (NMD) analysis of BRIP1 p.ArgR798Ter 
To investigate whether the protein truncating mutation p.Arg798Ter triggers nonsense mediated decay, we 
treated lymphoblastoid cell lines from a heterozygous carrier and wildtype controls with10 mg/ml 
cycloheximide for five hours. We extracted total RNA and DNA from treated and untreated cells with the 
AllPrep DNA/RNA Micro kit (QIAGEN Inc.), and then prepared cDNA with the QuantiTect Reverse 
Transcription Kit (QIAGEN Inc.). PCR Primers for DNA and cDNA analysis can be provided on request. The 
experiment was carried out in triplicate. 
 
Results 
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Truncating variants 
In analyses restricted to women of European ancestry the mutant allele was observed in 23 of 47,654 cases 
(0.050%) and 18 of 43,172 controls (0.04%) (OR 1.09, 95% CI 0.58-2.013, P = 0.79) (Table 2). Consistent 
results were obtained when analyses were restricted to women with known invasive breast cancer (OR 0.95, 
95% CI 0.49-1.83). When the analysis was restricted to studies without oversampling of cases with a family 
history and/or bilaterality, the results were very similar to those for the whole dataset (OR 1.09, 95% CI 0.56-
2.09, P = 0.81).  
In the SEARCH, BCFR and Peter MacCallum Cancer Centre studies we identified 34 truncating variants in 
cases (0.21%) and 19 in controls (0.23%) (combined OR 0.90, 95% CI 0.48-1.70, P=0.75) (Table 2 and 
Supplementary Tables 1-3). The carrier frequency in controls was similar to that observed in exome sequencing 
data from 60,706 individuals in the Exome Aggregation Consortium (http://exac.broadinstitute.org/:0.21%). 
There was no evidence of heterogeneity in the OR among studies (P=0.49, I
2
=0.0).  After elimination of the 
overlaps between BCAC and the SEARCH and BCFR datasets, the combined OR across all four studies for 
identified BRIP1 truncating variants was 0.98 (95% CI 0.62-1.54, P=0.93) (Table 2).  
There was weak evidence of an increased risk of estrogen receptor (ER) negative breast cancer for p.Arg798Ter 
carriers in BCAC (OR 2.25, 95% CI 0.93-5.46, P=0.07), but no evidence of an association with truncating 
variants in SEARCH (0.53, 95% CI 0.06-2.34, P=0.054; combined OR 1.71, 95% CI 0.77-3.80, P=0.19) (Table 
3). There was also weak evidence of an association with triple (ER/PR/HER2) negative disease in BCAC (OR 
3.62, 95% CI 0.99-13.2, P=0.05) but not in SEARCH  (combined OR 2.71, 95% CI 0.84-8.74, P =0.10); 
however, these analyses were based on only four and one triple negative case carrying the variant in BCAC and 
SEARCH, respectively. There was no evidence for an association with ER-positive disease in either dataset 
(combined OR 0.61, 95%CI 0.33-1.13, P=0.12).  
Nonsense mediated decay 
We performed Sanger sequencing on both cDNA and DNA of cycloheximide-treated and untreated wildtype 
and p.Arg798Ter lymphoblastoid cell lines (Figure 2). Sequencing chromatograms showed that the rare, 
truncating allele was much less abundant than the wildtype allele in cDNA from untreated cells, but not in the 
treated cells, consistent with the inhibition of nonsense mediated decay with cycloheximide.  
Missense variants 
We considered missense variants with a CADD score>20 as the most likely deleterious variants. There was no 
evidence for association between carrying one of these missense variants, as a set, with breast cancer risk in the 
combined dataset (OR 1.08, 95%CI 0.95-1.24, P=0.25; Table 4), though there was some weak evidence of 
association in the Peter MacCallum Cancer Centre study. One variant, p.Arg173Ser, accounted for the majority 
of carriers of likely deleterious variants in the sequencing studies; it was also genotyped in BCAC and showed 
no evidence of association (combined OR 1.07, 95% CI 0.93-1.23, P=0.35). None of the other missense variants 
genotyped in BCAC showed evidence for association (Table 1).  
Distribution of p.Arg798Ter by population 
Among European populations, there was substantial variation in the frequency of the p.Arg798Ter allele by 
country (P<.0001); the carrier frequency was approximately 0.1% in the UK, Ireland and Australia, but virtually 
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absent elsewhere in Europe. Forty-one of the 42 carriers shared a common haplotype of 21 markers across 
150kb (Supplementary Figure 1, Supplementary Table 4). In addition, we observed two occurrences among 
12,893 women of Asian ancestry, both from a Malaysian study (MYBRCA) and both carrying the common 
haplotype in Europeans, and two occurrences among 2,048 African-American women, one of which carried the 
founder European haplotype. These results suggest that the variant has arisen multiple times but that the 
majority of the carriers of p.Arg798Ter in Europeans have a common ancestral origin.  
Discussion 
BRIP1 is included on many cancer gene sequencing panels, and has been generally regarded as a “moderate 
risk” breast cancer susceptibility gene, together with other genes, including ATM, CHEK2 and PALB22 The 
evidence that deleterious mutations in these latter three genes confer an increased breast cancer risk is 
unequivocal, supported by large case-control, kin-cohort and segregation studies
22 33-37
.  In the case of BRIP1, 
however, it is notable that no large systematic studies have been published since the original study by Seal et al
6
  
(Supplementary Table 1),  although clear evidence of an association between truncating mutations and ovarian 
cancer risk has emerged
38 39
.  We sought to evaluate the evidence that protein truncating mutations in BRIP1 are 
associated with breast cancer, taking advantage of the large body of data generated as part of the iCOGS 
genotyping array. This allowed us to genotype one such variant, p.Arg798Ter, shown to be relatively frequent 
in previous studies, in more than 48,000 cases and 43,000 controls of European origin. In addition, we 
sequenced the coding region of BRIP1 in more than 16,000 cases and 8,000 controls, predominantly of 
European origin, from three studies. We found no evidence of an association with breast cancer risk either for 
p.Arg798Ter, or for carrying any truncating variant in the gene. The upper 95% confidence limit (1.54) 
excludes a twofold risk of breast cancer, often taken as a lower threshold for a moderate-risk allele
2
. 
We found weak evidence of an association between p.Arg798Ter and ER-negative disease and triple negative 
disease in BCAC, but not for truncating variants in the combined analysis. A recent study found eight BRIP1 
truncating variants in 1,853 triple negative breast cancer cases, slightly higher than the frequency observed in 
our sequence analysis
40
. Assuming that there  is association for triple negative breast cancer, a sample size of 
~1400 triple negative cases, that is approximately 3 fold larger than the current dataset,  would be required to 
exclude an odds ratio of 3 (upper 95% CI), assuming a large control set. Thus, while an association of this 
magnitude may exist for triple negative disease, this should be resolvable by larger studies. 
It remains possible that some subset variants in BRIP1 do confer more substantial risks of breast cancer. 
p.Arg798Ter is a classic protein truncating mutation, which we showed undergoes nonsense mediated decay. 
Rare homozygotes, with complete loss of the BRIP1 protein, are associated with Fanconi Anaemia
4
. Although 
the results from the sequence analyses found no other truncating variants of comparable frequency to 
pArg798Ter, additional founder mutations might exist at similar or greater frequency in other European or non-
European populations. We also found no evidence of association for missense variants, defined as potentially 
deleterious by CADD score; again the upper 95% confidence limit in this analysis exclude a two-fold risk, 
though it remains possible that individual missense variants might confer a more substantial risk, as occurs in 
ATM
41-43
. 
It also remains possible that truncating (or missense) variants are associated with a smaller (less than two-fold) 
risk of breast cancer (perhaps with a higher relative risk for certain disease subtypes). However, in this case 
even larger studies would be required to establish the association and to provide reliable risk estimates. 
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Moreover, this would place such variants in the same category as common risk SNPs and other modest risk 
variants, such as CHEK2 p.Ile157Thr and BRCA2 p.Lys3326Ter. If this were the case, the clinical implications 
would be quite different from those of established susceptibility genes, since the risks conferred by the variant 
would only be substantial if combined with other risk factors. 
These results highlight the importance of very large systematic studies to estimate disease risks associated with 
genetic variants. We conclude that there is no clear evidence for an association between protein truncating 
variants in BRIP1 and breast cancer risk. While BRIP1 screening might have utility for ovarian cancer risk 
prediction, in combination with other risk factors
39
, such variants should not be used for breast cancer risk 
prediction. 
Legends 
Figure 1. Cluster plot for genotype intensities for rs137852986 on the iCOGS array. Normalised intensities for 
the variant and wild-type allele for each individual are given by the X and Y co-ordinates, respectively. 
Individuals called as p.Arg798Ter carriers are indicated by green dots and non-carriers by blue dots. The red dot 
indicates a positive control individual known to carry the variant from prior sequencing.   
Figure 2. Sequencing of cDNA from a cycloheximide-treated and untreated lymphoblastoid cell line from a 
BRIP1 p.Arg798Ter carrier. Forward sequence of a) cDNA from cycloheximide-treated lymphoblastoid cell 
line, (b) cDNA from the untreated lymphoblastoid cell line and c) DNA sequence from the same cell line.  
Supplementary Figure 1.  Most probable haplotypes of markers across the BRIP1 region, for carriers of the 
p.Arg798Arg variant, based on 36 markers genotyped on iCOGS. p.Arg798Ter is marker 15; a list of the 
markers used is given in Supplementary Table 1. 44 carriers share a common haplotype consisting of 21 
markers across a 150kb interval (with the exception of one discrepant genotype for marker 12, rs11871134); for 
these individuals the shared haplotype is shown. Two carriers do not share the consensus haplotype – for these 
individuals both haplotypes (at the bottom of the figure) are given. Green indicates allele 1 and red indicates 
allele 2. Haplotypes from individuals of Asian and African-American ancestry, respectively, are highlighted as 
green and yellow respectively; the remaining haplotypes are from individuals of European ancestry. 
Supplementary Table 1. Published studies of BRIP1 mutation screening in breast/ovarian cancer families. 
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Table 1 Summary of missense variants tested for association with breast cancer risk in BCAC. 
rs number Position
1 
Substitution Protein alteration CADD
2 
Polyphen SIFT MAF
3 
OR (95%CI) P-value  
rs4988345 59924572 c.517C>T p.Arg173Ser 20.8 Probably 
damaging 
Deleterious 0.0043 1.05 
(0.91-1.21) 
0.49 
rs4988346 59924512 c.577G>A p.Val193Ile 0.342 Benign Tolerated 0.0044 1.11 
(0.97-1.28) 
0.13 
rs4988347 59924505 c.584T>C p.Leu195Pro 0.578 Benign Tolerated 0.0022 1.13 
(0.93-1.37) 
0.23 
rs28997569 59885956 c.790C>T p.Arg264Trp 16.72 Probably 
Damaging 
Deleterious 0.0011 1.01 
(0.76-1.34) 
0.96 
rs28997570 59885856 c.890A>G p.Lys297Arg 8.669 Benign Tolerated 0.0016 1.06 
(0.84-1.34) 
0.60 
rs4988350 59861668 c.1591T>G p.Phe531Val 23.8 Probably 
Damaging 
Tolerated 0   
rs4988349 59861640 c.1619A>T p.Gln540Leu 16.61 Possibly 
Damaging 
Tolerated 0   
rs137852986 59793412 c.2392C>T p.Arg798Ter 39 - - 0.00021 1.09  
(0.58-2.03) 
0.79 
rs28904918 59770797 c.2569A>G p.Ile857Val 18.50 Probably 
Damaging 
Tolerated 6x10
-5 
0.87 
(0.21--3.66) 
0.85 
rs4986764 59763347 c.2755T>C p.Ser919Pro 4.321 Benign Deleterious 0.42 1.00 
(0.98-1.01) 
0.66 
rs4988356 59763298 c.2804T>G p.Val935Gly 1.149 Benign Deleterious 2x10
-5 
0.44 
(0.039-5.00) 
0.510 
1
 hg19 (build 37) position 
2
Combined Annotation Dependent Depletion scores
20
 
3
MAF = Minor Allele Frequency 
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Table 2. Association between protein truncating variants in BRIP1 and breast cancer risk 
Study Case 
Carriers/Total (%) 
Control 
Carriers/Total (%) 
OR (95%CI) P-value 
BCAC 23/47,654 (0.05%)  18/43,172 (0.04%) 1.09 (0.58-2.03) 0.79 
SEARCH 24/13,213 (0.18%) 13/5,242   (0.25%) 0.73 (0.36-1.57) 0.36 
BCFR 4/1,313      (0.30%) 2/1,123      (0.27%) 1.71 (0.24-19.0) 0.69 
PeterMac 6/1,853      (0.38%) 4/2,001      (0.20%) 1.62 (0.38-7.82) 0.45 
COMBINED 
  
0.98 (0.62-1.54) 0.93 
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Table 3. Association between protein truncating variants in BRIP1 and breast cancer risk by subtype 
 ER-positive   ER-negative   Triple 
Negative 
  
Study Carrier/Total 
(%) 
OR (95%CI) P-value Carrier/Total 
(%) 
OR (95%CI) P-value Carrier/Total 
(%) 
OR 
(95%CI) 
P-value 
BCAC 4/27,680 
(0.01%)  
0.38  
(0.13-1.15)  
0.09 8/7,707 
(0.10%) 
2.25  
(0.93-5.46) 
0.07 4/2,983 
(0.13%) 
3.62 
 (0.99-13.2) 
0.05 
SEARCH 14/7,391 
(0.19%) 
0.76 
(0.36-1.63) 
0.56 2/1,521 
(0.13%) 
0.53  
(0.06-2.34) 
0.54 1/551 
(0.18%) 
 
0.73 (0.02-
4.89) 
1.0 
Combined  0.61 
(0.33-1.13) 
0.12  1.71  
(0.77-3.80) 
0.19  2.71  
(0.84-8.74) 
0.10 
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Table 4. Association between missense variants in BRIP1 with CADD score >20 and breast cancer risk. 
STUDY Case 
Carriers/Total (%) 
Control 
Carriers/Total (%) 
OR (95%CI) P-value 
BCAC 429/47,666 (0.90%) 370/43,176 (0.86%) 1.06 (0.92-1.22) 0.43 
SEARCH 276/13,213(2.1%) 107/5,242 (2.0%) 1.06 (0.85-1.32) 0.66 
BCFR 0/1,313 (0%) 1/1,123 (0.09%) -  
PeterMac 40/1,853 (2.2%) 28/2,001 (1.4%) 1.68 (1.02-2.82) 0.03 
COMBINED   1.08 (0.95-1.24) 0.25 
 
  
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1. Published studies of BRIP1 mutation screening in breast/ovarian cancer families 
Authors/Title Source country / 
Ethnicity 
Study design Mutation detection 
method 
Selection of cases Number of 
cases screened 
for BRIP1 
mutations 
Number of 
heterozygous cases  
Number of 
controls 
screened for 
BRIP1 mutations 
Number of 
heterozygous 
controls 
Comment 
Rutter et al Hum Mutat. 2003 
Aug;22(2):121-8.  
USA Candidate gene 
approach  
DHPLC and Sanger 
sequencing 
HBOC families + 
early onset BC 
cases (<35 y.o) 
79 8 30 4  
Lewis et al  Breast Cancer Res. 
2005;7(6):R1005-16. 
Australian Candidate gene 
approach;  mutation 
screening of familial 
BC cases and 
genotyping of 2 
specific missense  
p.P47A and 
p.M299I. 
DHPLC and Sanger 
sequencing 
Multiple-case BC 
families (KConFab) 
75 families 
screened for 
entire coding 
sequence + 253 
index cases 
screened for 
exons 3 and 7 
1 frameshift, 4 
missense 
(genotyped only 
for variants 
found in cases) 
1 missense  
Vahteristo et al BMC Cancer. 
2006 Jan 24;6:19. 
Finnish Candidate gene 
approach;  mutation 
screening of familial 
BC cases and 
genotyping of 2 
specific missense  
p.Val93Ile and the 
SNP ser919Pro. 
CSGE BC families 
negative for 
BRCA1/2 
43 1 rare missense 
(Val93Ile) 
183 (only 
genotyped for 
p.Val93Ile) 
0 p.Val93Ile 
identified in 1 
family then 
genotyped in 
346 additional 
BC cases and in 
183 controls 
Seal et al Nat Genet. 2006 
Nov;38(11):1239-41. 
UK Candidate gene 
approach with focus 
on LOF variants; 
case-control 
mutation screening 
study   
CSGE HBOC families 1,212 9 2,081 2 RR 2.0 (95%CI 
1.2-3.2) 
Guénard et al . J Hum Genet. 
2008;53(7):579-91. 
French Canadian  Candidate gene 
approach; likely 
deleterious variants 
subsequently 
genotyped in 73 
controls  
Sanger sequencing HBOC families 
negative for 
BRCA1/2 
96 0 0 N/A  
De Nicolo et al  
Clin Cancer Res. 2008 Jul 
15;14(14):4672-80. 
Italian Candidate gene 
approach in BC 
families 
Sanger sequencing HBOC families 
negative for 
BRCA1/2 and 
CHEK2 1100delC 
49 1 LOF 0 N/A  
Kurian et al  J Clin 
Oncol. 2014 Jul 1;32(19):2001-
9. 
USA Multi-gene panel 
testing of 42 genes 
Agilent SureSelect, 
MiSeq 
HBOC cases (NCCN 
guidelines) 
198 HBOC cases 
including 174 
BC cases, of 
whom 141 
tested negative 
for BRCA1/2 
0 LOF, 8 missense  0 N/A  
Castéra et al Eur J Hum Genet. 
2014 
Nov;22(11):1305-13. 
French Multi-gene panel 
testing ; 3 different 
capture design (16 
genes, 21 genes, 27 
genes) , all including 
BRIP1 
Agilent SureSelect, 
Illumina GAIIx 
Consecutive HBOC 
cases referred to 
Cancer Genetics 
Clinics for 
BRCA1/2 testing 
708 0 0 N/A  
Li et al  J Med Genet. 2015 Nov 
3. pii: jmedgenet-2015-
103452. 
doi: 10.1136/jmedgenet-2015-
103452. 
Australian Multi-gene panel 
testing of 17 genes; 
potentially relevant 
variants genotyped 
in other family 
members. 
Agilent Target 
Enrichment kit, Axeq 
technologies 
660 cases from 
multiple-case BC 
families (KConFab) 
660 9 LOF,  7 missense - - RR 0.47 (95%CI 
0.15-1.18) ; 
HR>1.56 
excluded                       
Aloraifi et al  Cancer Genet. 
2015 
Sep;208(9):455-63.  
Multi-ethnic: 10 
mutation screening 
studies on BRIP1 ; 
only 2 studies 
detected LOF 
variants. 
Meta-analysis on 6 
genes  performed 
on studies with 
high-risk BC cases 
with matched 
controls 
DHPLC, CSGE, Sanger 
sequencing 
Early onset (<50 
yo) or familial BC 
cases 
1,287 10 2,174 2  
Hirotsu et al Mol Genet 
Genomic Med. 2015 
Sep;3(5):459-66.  
Japanese Multi-gene panel 
testing of 25 DNA 
repair genes 
Ion AmpliSeq, Ion 
Proton, Life 
Technologies 
155 breast or 
ovarian cancer 
cases (94% with 
family history of 
BC), including 144 
cases negative for 
BRCA1/2 
144 0 0 N/A  
Rajkumar et al Asian Pac J 
Cancer Prev. 
2015;16(13):5211-7.  
Indian Multi-gene panel 
testing of 30 genes 
TruSeq Enrichment 
kit, Illumina HiScan 
SQ 
Family history of 
BC or early onset 
cases (<35 yo) 
91 0 0 N/A  
Lincoln et al . J Mol Diagn. 
2015 Sep;17(5):533-44.  
USA Multi-gene panel 
testing of 29 genes 
Agilent SureSelect, 
MiSeq or HISeq2500 
HBOC cases (NCCN 
guidelines) 
735 1 0 N/A  
Aloraifiet al FEBS J. 2015  
Sep;282(17):3424-37.   
Irish Multi-gene panel 
testing of 312 
genes. 
TruSeq Enrichment 
kit, Illumina HiSeq 
Familal BC cases 
negative for 
BRCA1/2 
104 0 101 0  
Maxwell et al Genet Med. 
2015 
Aug;17(8):630-8.  
USA Multi-gene panel 
testing of 22 genes 
Agilent SureSelect, 
sequencer? 
BRCA1/2 negative 
patients with early 
onset BC (<40 yo) 
278 1 0 N/A  
Cybulski Cet al  Clin Genet. 
2015 Oct;88(4):366-70. 
Polish Whole exome 
sequencing and 
evaluation of 12 
genes 
Agilent SureSelect 
human exome kit v4, 
HiSeq2000 
Familial cases 
negative for 
BRCA1, CHEK2 and 
NBS1 Polish 
founder mutation 
144 1 0 N/A  
Tung et al Cancer. 2015 Jan 
1;121(1):25-33.  
Multi-ethnic, 
Ashkenazi pop. 
Multi-gene panel 
testing of 25 genes 
RainDance 
Thunderstorm 
emulsion PCR, 
HiSeq2500 
Negative BRCA1/2 
cases tested at 
Myriad 
1781 (multi-
ethnic pop) + 
377 Ashkenazi 
Jews 
7 0 N/A  
Couch et al  J Clin Oncol. 2015  
Feb 1;33(4):304-11.  
12 studies, 
population from 
USA, Germany,UK, 
Finland, Greece 
Multi-gene panel 
testing of 17 genes 
Agilent custom 
capture, HiSeq 
TNBC cases 
unselected for 
family history of 
BC or OC 
1,824 8 0 N/A  
 
 
 
 
